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Of the many tasks that I do that are not directly connected
with teaching, research or column-writing (including review-
ing manuscripts and grant applications, sitting on various
advisory boards, miscellaneous administrative chores and so
on), the one that has given me the most satisfaction in recent
years is one I do for the Swedish Foundation for Strategic
Research. It involves reviewing applications for their Senior
Individual Grants. I don’t know anything quite like this grant
program anywhere else, but I know a lot of places, including
the USA, that could sure use one. 
The first Senior Individual Grants competition was
announced in 2003. Its stated purpose was to enable senior
scientists with a strong track record to take up new chal-
lenges. Applicants had to be working in Sweden, in the
research areas supported by the foundation (natural science,
engineering and medicine). The goal was to enable these
established investigators, in their 50’s and 60’s, to renew
their research and explore new ideas, preferably of a cross-
disciplinary, integrative nature. There was also an under-
standing that the proposed research should be of some clear
benefit to industry and society in Sweden. 
The competition had two phases. In the first phase, 18
grants, each of approximately €165,000 or $192,000 would
be awarded for a period of one year, to enable the grantee to
be relieved from ongoing tasks and assignments and to
develop, primarily through time spent working at another
institution, an entirely new research direction. In other
words, the grant was essentially a fully funded sabbatical
with that mission. 
Phase two kicked in a year later, when the foundation
announced a number of additional grants, each worth
approximately €660,000 or $770,000, for further research
activities over three years. Only those 18 grantees from the
first stage were eligible to apply. The purpose of the second
grant was, of course, to make it possible to turn the ideas
developed during the previous year into a completely new
research program. Twelve awards were eventually made at
this stage, meaning that a senior scientist who passed the
first phase of the competition had a 67% chance of getting
the additional three years of support. The combination of a
generous amount of money plus excellent odds of receiving
it ensured that the program would attract the attention of a
large number of senior scientists.
Applications were reviewed by both internal and external
referees. I was one of the external group, and the foundation
allowed me to follow the process all the way through - that is,
the applicants whom I had reviewed in phase 1 and who were
awarded one of the 18 planning grants were also sent to me
for review for the phase 2 competition (along with a few I
hadn’t seen before). Thus, I got to see exactly how these sci-
entists used their year of rethinking their research, and what
projects they now intended would come out of it. 
Talk about fascinating. The subject matter ranged from
systems biology to nanotechnology. Nearly all of the appli-
cants I reviewed at the first stage were distinguished scien-
tists with international reputations, but it had to be said that
most of them seemed to be on what I would call the down-
ward part of their careers. They were still publishing, but
generally doing things very similar to what they had been
doing for more than 20 years. They mostly weren’t working
at the cutting edge any more because the cutting edge had
moved away into other areas. In short, they were at the stage
of their scientific lives when many researchers find them-
selves unable to sustain the level of excellence they once dis-
played, and tend either to keep repeating themselves or
slowly wind down into irrelevance. Yet, given the chance to
come up with something new, a significant number of them
managed to find - through time spent in other labs, usually
in other countries - creative and important new ideas to
work on. In most cases this amounted to a significant change
in scientific direction, and in many it represented a shift to awhole new field. Some of the ideas were mundane, but most
were not, and many were highly imaginative. 
Why hadn’t these researchers done this before? The answer,
I think, lies in the way science is supported. Once you have
established yourself as a young scientist, the conservative
funding system, which tends to prefer giving money to
things that seem likely to work rather than to things that are
innovative and therefore risky, rewards those with a track
record so long as they continue to do the things they have a
track record in. Try working in a new area and you will often
be discounted as overly ambitious (read, ‘naive’) or unfo-
cused (read, ‘straying too far from your own turf’). Anyone
with a new idea faces these problems, of course, but they’re
particularly acute for the middle-aged scientist. Science is
seen as a young person’s game, and there is an unspoken
expectation that senior researchers - and often the fields
they work in - should slowly be put out to pasture, leaving
the racetrack for the colts and fillies. 
I think the notion that science belongs to the young has a lot
of truth in it, but I also don’t think it’s the whole story.
Studies of the aging brain have shown that, while younger
minds consistently trump their elders in situations that call
for fast reactions and cleverness, older people do better in
tasks that require wisdom and experience. Since creativity
often involves many of these skills, it isn’t reserved exclu-
sively to one generation. Certain types of creativity (poetry,
for example) do seem to be fueled best in the fires of youth,
but musical composition doesn’t show the same burn-out
with age, and neither does philosophy. Mathematics and the-
oretical physics clearly are the provinces of young scientists
(why is not clear), but biologists on average do their best
work in their forties and fifties, and many have done very
important work well past that. Genomics is too new a science
to judge how it will stack up in this regard, but given that at
its highest levels it seems to require both imagination and a
broad view of biology, I might predict that significant contri-
butions could be made by scientists of a wide range of ages.
It seems particularly silly to make it difficult for senior scien-
tists to change fields when the history of science in general,
and biology in particular, is filled with examples of break-
throughs made by researchers who came into a field from
outside, bringing with them a different perspective - and
sometimes new techniques - without the burden of the preju-
dices and unchallenged assumptions that often bedevil those
who have long labored in it. Senior scientists would seem to
be among the best equipped to do just that, but how are they
to change research directions when they are forever type-cast
to be what they have been? In the USA, some private founda-
tions such as the Ellison Medical Foundation and the McK-
night Endowment for Neuroscience do award research funds
largely on the basis of the novelty of the idea and the overall
track record of the applicant, without requiring a previous
history in the specific field, and anyone fortunate enough to
obtain support from the Howard Hughes Medical Institutes
can switch directions easily, but these are exceptions. The
rule is that once you have established yourself in a field it is
hard to break out of it, and the older you are the harder it
gets. Many senior scientists are indeed winding down, and
it is crucial to make way for bright young talent, but my
experience with the Swedish Senior Individual Grants
program leads me to believe that we may be wasting a sig-
nificant number of middle-aged scientists who could be
making significant contributions in new areas if only they
were given the chance. 
If the Swedes do have the right idea, how hard would it be to
implement such a program elsewhere? It should be highly
competitive, so even in a large country we’re not talking about
more than a few dozen awards. Let’s say, in the USA, 50. I like
the Senior Individual Grants model and it has seemed to
work, so why not copy it? The first year, the award would be
$200,000 to cover salary and expenses for the year of plan-
ning the new research program. Only scientists 50 years of
age and older would be eligible. That’s $10 million for the
first year of the program, not a large sum. Then out of those,
pick the 30 best proposed programs after the year is up, and
fund them for three years at $333,000 per year. Repeat the
program every four years. The steady-state cost would be
$10 million yearly. If the results after 12 years suggest that
there is indeed a significant untapped resource in the pool of
senior scientists, then we could consider expanding the
program, but for now, why not start small and see what
happens? The amount of money involved is modest enough
that a foundation could do it if the government doesn’t have
the will. 
As I said, reviewing the Senior Individual Grants proposals,
watching these middle-aged scientists get excited about their
new directions, and seeing the clever things they have come
up with, has been one of the most gratifying things I’ve done.
To think that it’s possible to renew your career at a time
when conventional wisdom might doubt that makes me
more optimistic about the fate of the aging scientist. All that
might be needed for many is the chance to show what they
can still do. And oh yes, in case you’re wondering: I’m 57.
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